In the EVG / COBI/FTC/TDF group through week 144 , HIV-1 from 8 patients ( 2.3 % ; 8/353 treated patients ) developed primary IN strand transfer inhibitor ( INSTI ) ( n = 6 ) and/or nucleoside RT inhibitor ( NRTI ) resistance substitutions ( n = 7 ) .